SwePub
Sök i SwePub databas

  Utökad sökning

Träfflista för sökning "WFRF:(Glimelius Bengt) ;srt2:(2000-2004)"

Sökning: WFRF:(Glimelius Bengt) > (2000-2004)

  • Resultat 31-40 av 66
  • Föregående 123[4]567Nästa
Sortera/gruppera träfflistan
   
NumreringReferensOmslagsbildHitta
31.
  •  
32.
  •  
33.
  •  
34.
  •  
35.
  • Hjalgrim, Henrik, et al. (författare)
  • Non-melanoma skin cancer may be a marker of poor prognosis in patients with non-Hodgkin's lymphoma
  • 2000
  • Ingår i: International Journal of Cancer. - 0020-7136 .- 1097-0215. ; 85:5, s. 639-642
  • Tidskriftsartikel (refereegranskat)abstract
    • According to recent results, patients with non-melanoma skin cancers are at increased risk of developing non-Hodgkin's lymphoma (NHL). The prognostic significance of this association is unknown. Two cohorts of patients with a first diagnosis of non-melanoma skin cancer and a subsequent diagnosis of either NHL (n = 170) or colon cancer (n = 435) were established using national cancer registry data in Denmark. Two other cohorts of patients in whom NHL (n = 600) or colon cancer (n = 1,541) was the patients' first known malignancy served as comparison groups. Mortality rates were compared using Cox's regression analysis. Among patients younger than 80 years at NHL diagnosis, a history of non-melanoma skin cancer was associated with significantly increased mortality [relative risk (RR) = 1.54; 95% confidence interval: 1.19-1.99]. This association was present in both men (RR = 1.38; 1.02-1.86) and women (RR = 2.15; 1.31-3.54) and was similar after both major subtypes of non-melanoma skin cancer. Overall, antedating non-melanoma skin cancer had no prognostic significance for colon cancer patients (RR = 1.00; 0.84-1.18). Whatever the underlying mechanism, our observation has potential clinical implications. If substantiated in other settings, NHL patients with prior non-melanoma skin cancer may constitute a subgroup of lymphoma patients in need of particular therapeutic attention.
  •  
36.
  • Högberg, Thomas, 1947-, et al. (författare)
  • A systematic overview of chemotherapy effects in ovarian cancer
  • 2001
  • Ingår i: Acta Oncologica. - 0284-186X. ; 40:2-3, s. 340-360
  • Tidskriftsartikel (refereegranskat)abstract
    • A systematic review of chemotherapy trials in several tumour types was performed by The Swedish Council of Technology Assessment in Health Care (SBU). The procedures for the evaluation of the scientific literature are described separately (Acta Oncol 2001, 40: 155-65). This overview on chemotherapy for epithelial ovarian cancer is based on a total of 176 scientific reports. Five meta-analyses including 17 291 patients, 33 prospective randomised studies including 12 340 patients, 36 prospective studies including 3593 patients and one retrospective study including 421 patients. The studies include approximately 33 642 patients. The conclusions reached can be summarized into the following points: ò Radically operated patients with low-risk early ovarian cancer (stage IA or IB non-clear-cell well-differentiated carcinomas or borderline tumours) have a very good prognosis and there is no indication for adjuvant therapy. ò Radically operated patients with high-risk early ovarian cancer (clear cell carcinomas or FIGO stage IA or IB moderately or poorly differentiated carcinomas or stage IC) have a substantial risk for micrometastatic disease. However, the role of adjuvant chemotherapy is unclear and such therapy should, thus, only be used within clinical trials. ò The median overall survival for patients with advanced (FIGO stages II-IV) ovarian cancer randomised to paclitaxel/platinum-containing chemotherapy in three large studies ranged between 36-39 months. Compared with historical data, this represents a six to seven times longer median survival time than after surgery only. The probability for long-term survival for patients treated with a paclitaxel/platinum combination is too early to define. ò In two prospective randomised trials in advanced ovarian cancer, paclitaxel in combination with cisplatin has provided a survival benefit over cyclophosphamide/cisplatin. Based on these trials, paclitaxel/cisplatin is considered to be the standard treatment. ò This choice of standard therapy might, however, be questioned based on the results of the hitherto largest randomised study in advanced ovarian cancer, ICON3, which is, as yet only available in abstract form. It compared paclitaxel/carboplatin with carboplatin only or a platinum combination (cyclophosphamide/doxorubicin/cisplatin). There were no statistically significant differences in progression-free or overall survival. The drug regimen in the control arms of the previous studies showing superiority of the paclitaxel-cisplatin combination may not have been the optimal non-paclitaxel platinum-containing regimen. ò Three randomised studies have compared carboplatin/paclitaxel with cisplatin/paclitaxel. All three are hitherto only published as abstracts with short follow-up precluding survival analyses. None of them shows any difference in response rates. All three show less toxicity and one also better quality of life with carboplatin. Thus, there are preliminary data supporting the substitution of cisplatin with carboplatin. ò Intraperitoneal therapy with cisplatin caused improved survival compared with intravenous therapy in one ramdomised study. Further studies have shown trends to better survival and longer progression-free interval with intraperitoneal therapy. The accrual to studies on intraperitoneal chemotherapy has been poor reflecting that it is a cumbersome and not easily accepted treatment. ò In advanced ovarian cancer, no convincing advantage has been shown from more dose-intensive chemotherapy, without cytokines or bone marrow stem cell support, compared with standard doses. ò High response rates are achieved with high-dose chemotherapy with stem cell support in the salvage situation but response duration is short. Phase III studies evaluating high-dose chemotherapy in the first-line situation are ongoing. Until supportive controlled clinical trials are presented, high-dose chemotherapy should be confined to clinical trials. ò Tumour response is frequently observed on re-treatment with the same drugs as given first-line in patients sensitive to first-line platinum-based chemotherapy with a long progression-free interval. Thus, in these patients treatment with a platinum/ paclitaxel combination might be recommended, albeit based on limited data. In patients resistant to first-line therapy, a number of single agents induce tumour responses in the range of 10-30%. The literature does not permit general treatment recommendations in these patients, which are recommended to be included in controlled clinical trials.
  •  
37.
  • Ihse, Ingemar, et al. (författare)
  • Riktlinjer för handläggning av patienter med pankreascancer
  • 2002
  • Ingår i: Läkartidningen. - Swedish Medical Association. - 0023-7205. ; 99:15, s. 1676-1683
  • Tidskriftsartikel (refereegranskat)abstract
    • Transabdominellt ultraljud är förstahandsundersökning vid misstänkt pankreascancer, följt av spiral-DT eller MR för mer definitiv diagnos. Tumörmarkörer har ingen plats i rutindiagnostiken. Spiral-DT är basen i resektabilitetsbedömningen. Resektion av tumören är en förutsättning för bot. Ett samband har påvisats mellan antalet resektioner som görs vid ett sjukhus årligen och postoperativ mortalitet. Långtidsöverlevnaden efter resektion är oförändrat kort medan postoperativ mortalitet minskat dramatiskt vid enheter som rapporterat sina resultat. Adjuvant behandling efter resektion bör endast ges inom ramen för kliniska studier. Det palliativa omhändertagandet har förbättrats främst genom utveckling inom endoskopi, interventionell radiologi, smärt- och nutritionsbehandling. Palliativ cytostatikabehandling bör endast ges selektivt utanför kliniska studier. Radioterapi har ingen dokumenterad effekt på överlevnaden vid icke-resektabel pankreascancer. Internationellt rekommenderas speciella behandlingsteam för pankreascancer med tillräckliga upptagningsområden (2–4 miljoner invånare).
  •  
38.
  • Jaeger, Ane Bonnerup, et al. (författare)
  • Correlates of heterosexual behavior among 23-87 year olds in Denmark and Sweden, 1992-1998
  • 2000
  • Ingår i: Archives of Sexual Behavior. - 0004-0002 .- 1573-2800. ; 29:1, s. 91-106
  • Tidskriftsartikel (refereegranskat)abstract
    • Correlates of heterosexual behavior, with a particular focus on early and high sexual activity, anal intercourse, prostitute visits, and HIV test activity, were studied. Telephone interviews were conducted with 852 randomly chosen persons who participated as controls in nationwide case-control studies of anogenital cancers in Denmark and Sweden, 1992-1998. While partner numbers and the practice of anal intercourse increased, age at sexual debut declined by 4-5 years (p < 0.001) and the maturation interval between menarche and first coitus halved (from 7 to 3 years, p < 0.001) between persons born in or before 1920 and those born in or after 1960. Women having high sexual activity were more often tested for HIV than less sexually active women, but men visiting prostitutes and those with prior STDs were not HIV tested more than other men. The increasing practice of anal intercourse, particularly among women with many partners, deserves attention, since this practice may erroneously be considered a safe sexual activity. Along with their partners, men with a history of STDs and those visiting prostitutes should be targeted in future safe sex campaigns, since these men appear to be inadequately HIV tested.
  •  
39.
  • Jestin, Pia, et al. (författare)
  • Elective surgery for colorectal cancer in a defined Swedish population.
  • 2004
  • Ingår i: Eur J Surg Oncol. - 0748-7983. ; 30:1, s. 26-33
  • Tidskriftsartikel (refereegranskat)abstract
    • AIMS: The aim of this study was to describe variability in compliance to clinical guidelines in colorectal cancer surgery related to hospital structure.METHODS: All patients registered in the databases of the Regional Oncologic Centre, operated upon electively for colon cancer between the start of the register in 1997 until 2000 (n=1771) and for rectal cancer between the start of the register in 1995 until 2000 (n=1841) were selected for analysis.RESULTS: There was no difference in 5-year survival rate between colon and rectal cancer (mean follow-up 2.6 and 3.0 years, respectively; p=0.22). There was a significant difference in frequency of preoperative liver scan depending on hospital category with an increase in colon cancer from 39 to 46% (p=0.02) and in rectal cancer from 42 to 64% (p<0.001). For colon cancer there was no difference, according to hospital category, in quotient sigmoid and high anterior resection to left-sided resection. Furthermore, high anterior resection was more common at university and general district hospitals (8%) compared with district hospitals (4%) (p=0.01). Sphincter-saving surgery was more common at university hospitals and district general hospitals than at district hospitals (low anterior/abdomino-perineal resection quotients 2.3, 2.4 and 1.6, respectively; p<0.001).CONCLUSIONS: Population-based audit forms an appropriate and valuable basis for quality assurance projects. In addition to describing compliance to guidelines and pointing to process steps that can be improved, such investigations may also indicate changes due to scientific development. Linked to case-costing data, such results may form an important basis for decisions about modifications in health care.
  •  
40.
  •  
Skapa referenser, mejla, bekava och länka
  • Resultat 31-40 av 66
  • Föregående 123[4]567Nästa
Åtkomst
fritt online (1)
Typ av publikation
tidskriftsartikel (63)
bokkapitel (3)
Typ av innehåll
refereegranskat (51)
övrigt vetenskapligt (15)
Författare/redaktör
Glimelius, Bengt, (66)
Sjödén, Per-Olow (12)
Enblad, Gunilla, (7)
Johansson, Birgitta (7)
Nordin, Karin, (6)
Sjoden, PO (6)
visa fler...
Berglund, Gunilla, (6)
Amini, Rose-Marie, (5)
Nygren, Peter, (5)
Wasteson, Elisabet, (4)
Kjellén, Elisabeth (4)
Frodin, JE, (4)
Molin, Daniel, (3)
Sundström, Christer (3)
Adami, Hans Olov (3)
Påhlman, Lars, (3)
Melbye, Mads (3)
Zackrisson, Björn, (3)
Glimelius, Ingrid, (3)
Sundstrom, C, (3)
Gustavsson, Anita (3)
Haapaniemi, Eva, (3)
Kjellén, E (3)
Forssell-Aronsson, E ... (3)
Berglund, Ake, (3)
Persson, C., (2)
Erlanson, Martin, (2)
Johansson, Jonas, (2)
Holmberg, Lars, (2)
Ekstrom, K, (2)
Frisch, Morten (2)
Gronberg, H, (2)
Berglund, A. (2)
Nordenskjöld, Bo, 19 ... (2)
Mattsson, Sören, (2)
Bergh, Jonas (2)
Montelius, Anders (2)
Isacsson, Ulf, (2)
Nordenskjold, B (2)
Hjalgrim, Henrik (2)
Storm, Hans (2)
Ekman, Tor (2)
Andersson, Michael (2)
Permert, Johan (2)
van Leeuwen, Flora E ... (2)
Turesson, Ingela, (2)
Pahlman, L, (2)
Lynch, Charles F (2)
Pukkala, Eero, (2)
Cavallin-Stahl, E (2)
visa färre...
Lärosäte
Uppsala universitet (60)
Karolinska Institutet (40)
Linköpings universitet (8)
Lunds universitet (7)
Göteborgs universitet (2)
Umeå universitet (2)
Språk
Engelska (61)
Svenska (3)
Odefinierat språk (2)
Forskningsämne (UKÄ/SCB)
Medicin och hälsovetenskap (43)
Naturvetenskap (2)

År

 
pil uppåt Stäng

Kopiera och spara länken för att återkomma till aktuell vy